The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?
Featured:
Francesc BoschDuring the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, What is the rationale behind the combination of glofitamab + polatuzumab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?
Bosch begins by discussing the bispecific antibody glofitamab, and the targeted conjugated polatuzumab, highlighting that since they have different targets (CD20 and CD79b, respectively), they can be used together. He outlines a trial discussed at ASH 2021 that found promising toxicity and complete response rates from the combination.